Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: Quantitative analysis of HER2 overexpression effects

被引:0
|
作者
Hendriks, BS
Opresko, LK
Wiley, HS
Lauffenburger, D [1 ]
机构
[1] MIT, Dept Chem Engn, Biol Engn Div, Cambridge, MA 02139 USA
[2] MIT, Canc Res Ctr, Cambridge, MA 02139 USA
[3] Pacific NW Natl Lab, Environm & Hlth Sci Div, Richland, WA 99352 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Elevated expression of human epidermal growth factor receptor 2 (HER2) is known to alter cell signaling and behavioral responses implicated in tumor progression. However, multiple diverse mechanisms may be involved in these overall effects, including signaling by HER2 itself, modulation of signaling by epidermal growth factor receptor (EGFR), and modification of trafficking dynamics for both EGFR and HER2. Because these processes are so tightly interrelated, the net effect of HER2 overexpression is difficult to reliably attribute to any single particular mechanism. To take an important first step toward dissecting the effects of HER2 overexpression on cell responses in terms of the various specific underlying mechanisms, we have developed and validated a quantitative model of the relevant trafficking processes. We then use our model for successful prediction of EGFR and HER2 level and location changes attributable to HER2 overexpression in 184A1 human mammary epithelial cells expressing a series of HER2 levels by retroviral infection. Model predictions are based on our independent experimental measurement of key trafficking parameters for both EGFR and HER2. In terms of trafficking processes, HER2 overexpression reduces the EGFR internalization rate constant and increases the fraction of EGFR recycled. Consequently, our model successfully predicts that HER2 increases the overall level of activated EGFR by both enhancing its recycling and reducing its internalization, but it increases activated EGFR localization at the cell surface almost solely by its reduction of internalization. Furthermore, the model also successfully predicts the effects of monoclonal antibody 2C4, which interferes with HER2/EGFR heterodimerization, on EGFR and HER2 levels and compartmental locations. We anticipate that this model should ultimately be useful in parsing the relative contributions of direct effects of HER2 via signaling vis-a-vis indirect effects of HER2 via modification of EGFR signaling.
引用
收藏
页码:1130 / 1137
页数:8
相关论文
共 50 条
  • [31] Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression
    Quddus, M. Ruhul
    Hansen, Katrine
    Tantravahi, Umadevi
    Sung, C. James
    GYNECOLOGIC ONCOLOGY REPORTS, 2020, 32
  • [32] The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma
    Ye, D
    Maitra, A
    Timmons, CF
    Leavey, PJ
    Ashfaq, R
    Ilaria, RL
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (06) : 459 - 466
  • [33] Investigation of Affinity at Binding Site Between Human Epidermal Growth Factor Receptor 2 (HER2) and Herceptin
    Kondrashova, Maria
    Miller, Bill
    FASEB JOURNAL, 2017, 31
  • [34] Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2)
    Seyedmirzaei, Homa
    Keshavarz-Fathi, Mahsa
    Razi, Sepideh
    Gity, Masoumeh
    Rezaei, Nima
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1235 - 1244
  • [35] Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer
    Awada, Gil
    Gombos, Andrea
    Aftimos, Philippe
    Awada, Ahmad
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (01) : 91 - 101
  • [36] Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature
    Alotaibi, Abdullah Mislat
    Alqarni, Mohammed Ali
    Alnobi, Abdelrahman
    Tarakji, Bassel
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2015, 9 (02) : ZE4 - ZE8
  • [37] Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a large scale metastatic colorectal cancer (mCRC) trial.
    Adenis, A
    Aguilar, EA
    Robin, YM
    Miquel, R
    Penault-Llorca, F
    Castañón, C
    Queralt, B
    Eggleton, SP
    van den Berg, N
    Wilke, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 278S - 278S
  • [38] Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
    Laokulrath, Natthawadee
    Gudi, Mihir
    Salahuddin, Syed Ahmed
    Chong, Angela Phek Yoon
    Ding, Cristine
    Iqbal, Jabed
    Leow, Wei Qiang
    Tan, Benjamin Yongcheng
    Tse, Gary
    Rakha, Emad
    Tan, Puay Hoon
    HISTOPATHOLOGY, 2024, 85 (03) : 371 - 382
  • [39] Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
    Kim, Min Chong
    Kang, Su Hwan
    Choi, Jung Eun
    Bae, Young Kyung
    JOURNAL OF BREAST CANCER, 2020, 23 (05) : 484 - 497
  • [40] A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer
    Nixon, N. A.
    Hannouf, M. B.
    Verma, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 89 : 72 - 81